Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements

Yang Wang, Na Zhu, Jing Liu, Fang Chen, Yang Song, Yue Ma, Zhuo Yang, Danbo WangJournal of Translational Medicine 2025 · DOI

TL;DR

This review dives deep into the complex tumor microenvironment (TME) of ovarian cancer (OC), revealing how its intricate cellular and molecular components drive metastasis, therapy resistance, and poor patient outcomes. By dissecting the roles of various cells and factors within the TME, the paper highlights promising new avenues for therapeutic targets and clinical advancements in tackling this deadly disease.

What Problem Does This Paper Address?

Ovarian cancer (OC) is a devastating disease, notorious for its late-stage diagnosis and widespread peritoneal metastasis, leading to poor prognoses despite current treatments. Unlike many other cancers, OC primarily spreads through the peritoneal cavity, a process heavily influenced by the "seed and soil" hypothesis – where tumor cells (seeds) interact with a compatible microenvironment (soil). This paper addresses the critical knowledge gap surrounding the tumor microenvironment (TME) in OC, specifically how its complex interplay of cells, extracellular matrix, and signaling molecules orchestrates metastasis, promotes resistance to therapies, and ultimately dictates patient survival. Understanding these intricate interactions is crucial for developing more effective treatments.

Methods

This paper is a comprehensive review, synthesizing existing research rather than presenting novel experimental data. The authors meticulously analyze and integrate findings from numerous studies to build a detailed picture of the OC TME. Their approach involves:

  • Literature Synthesis: Compiling and critically evaluating a vast body of published research on OC metastasis and the TME.
  • Component Analysis: Deconstructing the TME into its key cellular (immune cells, fibroblasts, adipocytes, endothelial cells, mesothelial cells, stem cells) and non-cellular (extracellular matrix, exosomes) components.
  • Functional Characterization: Describing the specific roles and mechanisms by which each TME component contributes to OC progression, metastasis, immune evasion, and therapy resistance.
  • Clinical Trial Overview: Summarizing ongoing clinical trials that target TME components, offering insights into potential therapeutic strategies.

Datasets

Not discussed in the paper. This is a review article that synthesizes existing research.

Key Insights and Ideas

  • The Omentum as a Metastatic Hub: The omentum, rich in adipose tissue, is a prime site for OC metastasis, acting as an ideal "soil" due to its unique microenvironment that supports tumor cell implantation and growth.
  • TME Orchestrates Metastasis: The TME isn't just a passive bystander; it actively prepares a "pre-metastatic niche" by fostering an immunosuppressive environment and remodeling the extracellular matrix, paving the way for tumor cell dissemination.
  • Immune Cell Plasticity is Key: Immune cells within the TME, particularly tumor-associated macrophages (TAMs), exhibit remarkable plasticity. Their polarization towards immunosuppressive (M2) phenotypes is a critical driver of OC progression and resistance.
  • Stromal Cells are Active Players: Cancer-associated fibroblasts (CAFs) and adipocytes are not merely structural components but actively contribute to OC metastasis and chemoresistance by secreting growth factors, remodeling the ECM, and providing metabolic support.
  • Exosomes as Communication Messengers: Tumor-derived exosomes act as crucial intercellular communicators, influencing various TME components to promote metastasis, immune evasion, and drug resistance.
  • Targeting the TME is the Future: The review strongly advocates for TME-targeting therapies, highlighting the potential of novel strategies like CAF-targeted therapies, anti-angiogenic agents, and immune checkpoint inhibitors, many of which are currently in clinical trials.

Key Results

This review doesn't present quantitative results in the traditional sense, as it's a synthesis of existing literature. However, the key "results" are the comprehensive understanding and detailed descriptions of:

  • The multifaceted roles of various TME components: From immune cells like TAMs and TANs to stromal cells like CAFs and adipocytes, and even non-cellular elements like exosomes and ECM, the paper meticulously details their contributions to OC metastasis and therapy resistance.
  • The intricate signaling pathways involved: The review highlights numerous molecular pathways (e.g., TGF-β, NF-κB, JAK/STAT, PI3K/Akt) that mediate the crosstalk between tumor cells and the TME, driving disease progression.
  • The current landscape of TME-targeted clinical trials: The extensive table of ongoing clinical trials provides a snapshot of the therapeutic strategies being explored, indicating a significant shift towards targeting the TME for OC treatment.

Limitations and Future Work

The authors acknowledge several limitations and suggest future research directions:

  • TME Heterogeneity and Treatment Response: The molecular heterogeneity of the TME across different OC subtypes and its impact on treatment response remain poorly understood.
  • Limitations of Current Models: Traditional 2D cell lines and xenograft models fail to fully replicate the complex spatiotemporal dynamics of the TME in peritoneal metastasis, particularly metabolic interactions.
  • Immunotherapy Mechanisms: The precise mechanisms underlying immunotherapy resistance, especially the synergistic effects of multiple immunosuppressive signals and antigen presentation defects, require further elucidation.

Future Work Suggestions:

  • Advanced Technologies: Employ single-cell transcriptomics, spatial metabolomics, and proteomics to understand TME heterogeneity and guide individualized therapies.
  • 3D Organoid Systems: Develop 3D organoid co-culture systems to better simulate the TME and screen for combination therapies.
  • Immune Microenvironment Remodeling: Investigate co-expression patterns of checkpoint molecules and design bispecific antibodies or epigenetic regulators to enhance T cell function and antigen presentation.
  • Personalized Treatment Strategies: Integrate patient-specific data, genomic analyses, and molecular assays to develop tailored therapeutic approaches.

Summary updated

Abstract

Ovarian cancer (OC) is the most lethal gynecological malignancy worldwide, characterized by heterogeneity at the molecular, cellular and anatomical levels. Most patients are diagnosed at an advanced stage, characterized by widespread peritoneal metastasis. Despite optimal cytoreductive surgery and platinum-based chemotherapy, peritoneal spread and recurrence of OC are common, resulting in poor prognoses. The overall survival of patients with OC has not substantially improved over the past few decades, highlighting the urgent necessity of new treatment options. Unlike the classical lymphatic and hematogenous metastasis observed in other malignancies, OC primarily metastasizes through widespread peritoneal seeding. Tumor cells (the "seeds") exhibit specific affinities for certain organ microenvironments (the "soil"), and metastatic foci can only form when there is compatibility between the "seeds" and "soil." Recent studies have highlighted the tumor microenvironment (TME) as a critical factor influencing the interactions between the "seeds" and "soil," with ascites and the local peritoneal microenvironment playing pivotal roles in the initiation and progression of OC. Prior to metastasis, the interplay among tumor cells, immunosuppressive cells, and stromal cells leads to the formation of an immunosuppressive pre-metastatic niche in specific sites. This includes characteristic alterations in tumor cells, recruitment and functional anomalies of immune cells, and dysregulation of stromal cell distribution and function. TME-mediated crosstalk between cancer and stromal cells drives tumor progression, therapy resistance, and metastasis. In this review, we summarize the current knowledge on the onset and metastatic progression of OC. We provide a comprehensive discussion of the characteristics and functions of TME related to OC metastasis, as well as its association with peritoneal spread. We also outline ongoing relevant clinical trials, aiming to offer new insights for identifying potential effective biomarkers and therapeutic targets in future clinical practice.
BibTeX
@article{wang2025role,
  author = {Yang Wang and Na Zhu and Jing Liu and Fang Chen and Yang Song and Yue Ma and Zhuo Yang and Danbo Wang},
  title = {{Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements}},
  journal = {Journal of Translational Medicine},
  year = {2025},
  doi = {10.1186/s12967-025-06508-0},
}
Figure